Clinical Trial Update: Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies [Phase 3]

View source ↗

Summary

Phase 3 randomized study evaluating obicetrapib added to maximum tolerated lipid-modifying therapies has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Dyslipidemia
• Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• Obicetrapib (obicetrapib)

Snippet

Sponsor: NewAmsterdam Pharma | Conditions: Dyslipidemias, High Cholesterol | Phase 3 | Status: COMPLETED | Results posted: 2025-09-19